Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir

Pharmacokinetics, Pharmacodynamics and Genital Tract Viral Shedding in HIV+ Women Using Combined Oral Contraceptives and Raltegravir

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01597180

Enrollment

Registered

2012-05-11

Start date

2012-07-31

Completion date

2014-03-31

Last updated

2014-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

contraception, HIV, pharmacokinetics, pharmacodynamics

Brief summary

The purpose of this trial is to learn about potential interactions between raltegravir and a birth control pill in HIV+ women. The investigators plan to enroll HIV+ women who are on steady state raltegravir containing highly active antiretroviral therapy (HAART), ages 20-40, inclusive, who report regular monthly menses. The investigators will investigate drug interactions of raltegravir, ethinyl estradiol (EE) and levonorgestrel (LNG). All women will be receiving raltegravir as part of their regular medical care. Women will be enrolled in the study for approximately 8 months.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Women between 20-40 years of age with regular monthly menses * If over age 35 then must not use tobacco * Negative pregnancy test * No known allergy to raltegravir * No known history of phenylketonuria * Undetectable HIV viral load * No active liver disease as determined by medical history and normal AST and ALT * No history of hepatic adenomas, carcinomas or benign liver tumors * Ho history of thrombophlebitis of thromboembolic disease * No history of deep vein thrombosis * No history of cerebral vascular or coronary artery disease * No known or suspected carcinoma of the breast * No undiagnosed abnormal genital bleeding * Not taking concomitant CYP 450 inducing medications such as anti-seizure medications * No use of oral contraceptives, depot-medroxyprogesterone acetate, contraceptive ring or patch within two months of screening * No cholestatic jaundice of pregnancy or jaundice with prior contraceptive pill use * Has used raltegravir prior to screening * Has no history of malignancy of the genital tract (e.g. cervical cancer, ovarian cancer, endometrial cancer) * Must not have had an abnormal pap test defined without resolution in the last 18 months.

Design outcomes

Primary

Measure	Time frame
Change in cervicovaginal fluide milieu	—

Countries

United States

Outcome results